Replimune Prices $150 Million Common Stock and Pre-Funded Warrant Offering
Replimune Group (Nasdaq: REPL) priced an underwritten offering of 9,701,490 common shares at $12.06 per share and pre-funded warrants for 2,736,340 shares at $12.0599 per warrant. Gross proceeds are expected to total about $150 million before underwriting and expenses. The deal is expected to close Aug. 11, 2026.
How this was made
The 30-second read
Why it matters
Pricing details (share count, $12.06 price, pre-funded warrant terms, and ~$150M gross proceeds) create an immediate financing overhang and can affect valuation expectations into and through the Aug. 11 close.
Market read
This is a concrete, time-bound capital raise with defined pricing and close timing, making it a tradable catalyst for REPL around the offering execution window.
What to watch
The pre-funded warrant structure and near-term close timing can drive short-term positioning dynamics; without stated use-of-proceeds, traders may focus on dilution math rather than milestone de-risking.
Background
Replimune is a commercial-stage biotech developing oncolytic immunotherapies, with TUDRIQEV approved under accelerated approval in combination with nivolumab for advanced melanoma.
Ticker impact
Replimune priced an underwritten offering of 9,701,490 common shares at $12.06 plus pre-funded warrants for 2,736,340 shares, raising about $150M gross.
Likely near-term downside or volatility around the offering close, with sentiment dependent on whether the market views proceeds as sufficient to de-risk the next milestones.
The article discloses concrete deal terms (size, price, close date) but not incremental guidance or use-of-proceeds specifics, so the primary tradable effect is dilution and financing overhang.
Market effects
Adds to the financing narrative for commercial-stage biotech, where equity issuance can signal cash runway needs and affect peer sentiment.
Primarily impacts US small/mid-cap biotech liquidity and risk appetite for similar names.
Limited direct global spillover; could modestly influence investor appetite for oncolytic immunotherapy financings.
Counterpoint
If investors interpret the $150M raise as extending runway through key clinical/regulatory milestones, the stock could stabilize after the initial dilution overhang.
Key entities
- companyReplimune Group, Inc.
Nasdaq-listed commercial-stage biotech that priced a $150M underwritten common stock and pre-funded warrant offering.
- financial_advisorLeerink Partners
Bookrunning manager for the offering.
- financial_advisorJ.P. Morgan Securities LLC
Bookrunning manager for the offering.
- financial_advisorCantor Fitzgerald & Co.
Bookrunning manager for the offering.
